Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 6Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Lymphoma, Follicular 4Lymphoma, T-Cell, Peripheral 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Mastocytosis, Systemic 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Kidney Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 9Rituximab 6Tacrolimus 5Busulfan 5fludarabine phosphate 4blinatumomab 4Vincristine 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4fludarabine 3Whole-Body Irradiation 3Valganciclovir 3Everolimus 3venetoclax 2dacetuzumab 2cobomarsen 2Thiotepa 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Filgrastim 2Epoetin Alfa 2Antilymphocyte Serum 2sargramostim 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoproliferative Disorders × denileukin diftitox × Clear all
NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡